Treatability with ibrutinib plus venetoclax in patients with CLL in the real-world. the eric international thrive study
Andrea Visentin(University of Padua), Giuseppe Petruzzellis(Ospedale Santa Maria della Misericordia di Udine), Fabiana Esposito(Ente Ospedaliero Cantonale), Isacco Ferrarini(University of Verona), Leonidas Benetatos(University of Ioannina), Maurizio Cavallari(Arcispedale Sant'Anna), Persefoni Talimtzi(Centre for Research and Technology Hellas), Dominik Chraniuk(Provincial Polyclinical Hospital in Toruń), Vanessa Innao, Maura Nicolosi(Palmetto Hematology Oncology), Sara Pepe(Sapienza University of Rome), Massimo Gentile(Azienda Ospedaliera di Cosenza), Marina Deodato(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Alexandros Machairas(Laiko General Hospital of Athens), Luca Laurenti(Sapienza University of Rome), Lydia Scarfò(IRCCS Ospedale San Raffaele), Anastasia Chatzidimitriou(Karolinska Institutet), Francesca Cibien(University of Ferrara), Horia Bumbea(Carol Davila University of Medicine and Pharmacy), Ernesto Pérez Persona(Navarrabiomed), Lucia Farina(Fondazione IRCCS Istituto Nazionale dei Tumori), Krzysztof Jamroziak(Instytut Hematologii i Transfuzjologi), Michael Doubek(Central European Institute of Technology), Laura Ballotta(Azienda Sanitaria Universitaria Integrata di Trieste), Maria Ilaria Del Principe(University of Rome Tor Vergata), Javier Loscertales(The University of Texas MD Anderson Cancer Center), Maria Kislova(Botkin Hospital), Roberta Murru, Thomas Chatzikonstantinou(G. Papanikolaou General Hospital), Nilla Maschio(Ospedale Castelfranco Veneto), Antonio Cuneo(Arcispedale Sant'Anna), Jacopo Olivieri(Ospedale Santa Maria della Misericordia di Udine), Enrico Lista(Arcispedale Sant'Anna), Anna Maria Frustaci(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Anna Christoforidou(University of Crete), Eva Minga(Centre for Research and Technology Hellas), Maria K. Angelopoulou(Laiko General Hospital of Athens), Elżbieta Kalicińska(The University of Melbourne), Andrea Galitzia(Ospedale di Prato Santo Stefano), Francesca Martini(University of Pisa), Carolina Pavlovsky(Unknown), Ioannis Kyriakou(G. Papanikolaou General Hospital), Gianmarco Favrin(Policlinico San Matteo Fondazione), Miguel Arturo Pavlovsky(Universidad de Buenos Aires), Giorgia Marcato(Istituto Oncologico Veneto), Enrico Derenzini(University of Milan)
Cited by 0
Related Papers
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
|Blood|2013|391
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
|Leukemia|2018|250